Dingchi Bio Completes Tens of Millions RMB Series B1 Financing to Advance Innovative Animal Health Products and Biopharmaceutical Raw Materials

In June 2023, vbiosci, an R&D-driven innovative biotechnology enterprise, completed a Series B1 financing round amounting to tens of millions of yuan. The round was exclusively invested by the Capital Big Health Industry Fund managed by Huagai Capital. This financing will further accelerate the pipeline R&D and industrialization of vbiosci’s innovative animal health products (vaccines, biologics, and pet care products), and also promote the R&D and industrialization efforts of its wholly-owned subsidiary, Yishengke, in key raw materials for biopharmaceuticals (serum-free culture media and purification resins), thereby providing customers with better products and superior services.

Huagai Capital, established in 2012, is a private equity investment firm co-founded by professionals from renowned domestic and international investment institutions. With the vision of “becoming the most trusted capital partner for entrepreneurs and investors,” the company focuses on private equity investments in the healthcare and technology sectors, committed to fostering the growth of small and medium-sized enterprises into industry leaders. Currently, the firm manages assets totaling approximately RMB 20 billion.